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doi:10.1016/j.jfma.2011.06.011Background/Purpose: Human growth hormone (GH) has been successfully used in children with
GH deficiency (GHD). However, there are few published data on the effect of GH in Taiwanese
children with GHD.
Methods: We performed a retrospective cohort study to identify factors influencing the effect
of GH therapy on ethnic Chinese children with GHD in Taiwan. Idiopathic GHD can be classified
into isolated GHD (IGHD) and multiple pituitary hormone deficiency (MPHD). The study looked
at the effect of GH on the auxological, biochemical, and imaging parameters of 51 patients (13
girls and 38 boys) in three different diagnostic groups: MPHD (nZ 12), IGHD (nZ 8), and tran-
sient GHD (TGHD; nZ 31). TGHD is defined as a GH peak >10 mg/L in re-evaluation by two GH
stimulation tests approximately 6 months after discontinuation of GH therapy.
Results: The height velocity for first-year GH therapy was 7.61  1.46, 8.14  1.92, and
9.99  2.75 cm/y in the TGHD, IGHD, and MPHD groups, respectively. After post hoc compar-
ison, the MPHD group had a significantly accelerated height velocity in the first year compared
to the TGHD group. Correlation analysis showed that a change in height standard deviation
score (SDS) in the first year had a significant negative correlation with the following variables:
peak GH (rZ 0.52, p < 0.001), pretreatment height SDS (rZ 0.49, p < 0.001), and height-
target height (Ht-TH) SDS (rZ 0.49, p < 0.001). Change in height SDS in the first 2 years had
a significantly negative correlation with peak GH (r Z 0.51, p < 0.001), insulin-like growth
factor-1 SDS (r Z 0.35, p Z 0.022), height SDS (r Z 0.60, p < 0.001), difference between
bone age and chronological age (rZ 0.46, pZ 0.001), and Ht-TH SDS (rZ 0.50, pZ 0.001).
After using multiple linear regression, the pretreatment GH peak value was found to be signif-
icantly associated with height increments after 1 year of GH treatment (BZ 0.07, pZ 0.014).ediatric Endocrinology and Genetics, Department of Pediatrics, Chang Gung Memorial Hospital, Chung
Taoyuan, Taiwan.
.org.tw (F.-S. Lo).
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356 Y.-H. Huang et al.Conclusion: The administration of GH to children with GHD results in a pronounced acceleration
in linear growth during the first year of treatment, especially in those with MPHD. The diagnosis
of GHD requires comprehensive auxological, biochemical, and brain magnetic resonance
imaging assessment. We also suggest that patients with GHD, specifically IGHD, must undergo
a re-evaluation of GH secretion after completion of GH therapy.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
For more than 50 years, human growth hormone (GH) has
been used in GH deficiency (GHD).There are few published
data reporting factors predicting the effect of GH on
Taiwanese children with GHD. The conventional study of GH
secretion, diagnosis, and treatment of GHD during child-
hood and adolescence is still controversial. The diagnosis of
GHD is a multifaceted process requiring comprehensive
clinical and auxological assessment, combined with the
biochemical testing of the GHeinsulin-like growth factor
(IGF) axis and evaluation with brain magnetic resonance
imaging (MRI).1
The etiology of GHD may be idiopathic or associated
with organic causes, such as tumor, surgery, or irradiation
of the sellar area. Idiopathic GHD may be classified into
isolated GHD (IGHD) and multiple pituitary hormone defi-
ciency (MPHD) by its association with a deficiency of one or
more anterior pituitary hormones during provocation tests.
Morphological alterations on brain MRI in patients with GHD
include pituitary hypoplasia, absence or interruption of the
pituitary stalk, and an absent or ectopic posterior lobe.
Most subjects previously labeled as having IGHD with
a normal pituitary MRI or an isolated small pituitary gland
have been reported to show a normalization of GH secre-
tion after completing their growth.2e4 This represents
a condition of transient GHD (TGHD) of unknown origin, an
absence of pubertal steroids, or simply unreliability and
variability of the GH provocation tests.5
In 2004, we reported that MRI findings in the
hypothalamic-pituitary area can be correlated with the
severity of hypopituitarism.6 Patients with MPHD had a low
height, peak GH level, and IGF-1 standard deviation score
(SDS) and greater bone age (BA) delay than partial those with
IGHD or severe IGHD before GH therapy. In this investigation,
we performed a retrospective cohort study of the effect of
GH on the auxological, biochemical, and imaging parameters
of 51 ethnic Chinese children in three different diagnostic
groups of GHD (TGHD, IGHD, and MPHD) and analyzed the
variables predicting the response to GH treatment.Patients and methods
Patients
The retrospective cohort study comprised 51 patients (13
females and 38 males) with GHD who were receiving GH
treatment and were followed up in the Division of Pediatric
Endocrinology and Genetics at Linkou Chang-Gung Memorial
Hospital from Aug 1996 to July 2010. Patients presenting the
following criteria were diagnosed as having GHD: (1) peak GHresponse less than 10 mg/L after two GH provocation tests
(insulin and clonidine stimulation test); (2) severe short
stature (height < 3rd centile) or low height velocity < 4 cm/
y7; and (3) BA8 retarded by at least 2 SDS from the chrono-
logical age (CA). The height of the patient is expressed as an
SDS (see the supplementary methods), and the report of the
Department of Physical Education and Sports of the Ministry
of Education in Taiwan was used as to define the standards.9
Anterior pituitary function was evaluated by combined
pituitary function testing: insulin tolerance test for GH and
cortisol secretion; thyrotropin-releasing hormone test for
thyroid-stimulating hormone (TSH) and prolactin secretion;
and gonadotropin-releasing hormone test for follicle-
stimulating hormone and luteinizing hormone secretion
(see the supplementary methods).10 None of the patients
received sex steroid priming before the GH stimulation
tests.
Methods
Based on the results of endocrinological evaluation,
patients were divided into three groups: (1) patients with
MPHD (nZ 12), defined as GH peak concentration < 10 mg/
L accompanied by a deficit of one or more anterior pituitary
hormones; (2) patients with IGHD (n Z 8), defined as a GH
peak < 10 mg/L; and (3) patients with TGHD (n Z 31),
defined as a GH peak >10 mg/L on re-evaluating GH status
by pharmacological stimulation (insulin stimulation test or
clonidine test) approximately 6 months after discontinua-
tion of GH therapy considering the initial diagnosis as MPHD
(n Z 2) or IGHD (n Z 29) (Fig. 1).
MRI was performed after diagnosis of GHD for 50 patients
(see the supplementary methods). The one remaining
patient underwent a brain computed tomography study. All
images were evaluated by one radiologist. The height of the
pituitary gland was measured on the midline sagittal plane
perpendicular to the floor of the sella turcica to the highest
point of the surface of the superior gland, located at the
point of insertion on the pituitary stalk.11 The presence of
the stalk was determined, and its width was evaluated on
both the coronal and sagittal images. The stalk was classi-
fied as normal or as showing dysgenesis [including being
thin (<2.13 mm),12 interrupted,13 or absent]. The bright
spot of the posterior pituitary was evaluated in both the
coronal and sagittal images. It was considered to be ectopic
if located outside the sella turcica.13 The age of the 50
patients at the time of MRI ranged from 3.21 to 19.12 years
(10.69  3.24 years).
In the MPHD group, two patients had GHD accompanied
by TSH, adrenocorticotropic hormone, and gonadotropin
deficiency, two had GHD with TSH and gonadotropin defi-
ciency, three with TSH deficiency alone, two with
Figure 1 Flowchart showing the results of the growth hormone (GH) test expressed in the transient growth hormone deficiency
(TGHD), isolated growth hormone deficiency (IGHD; <10 mg/L), and multiple pituitary hormone deficiency (MPHD; <10 mg/L
accompanied by one or more anterior pituitary hormone deficits) groups before and approximately 6 months after GH treatment.
Growth hormone therapy in growth hormone deficiency 357antidiuretic hormone deficiency, two with gonadotropin
deficiency, and one with adrenocorticotropic hormone
deficiency. These patients were treated with appropriate
hormone replacement. Sex steroid replacement therapy
was considered in patients with gonadotropic hormone
deficiency and poor secondary sexual development despite
an appropriate BA having been achieved (13 years in boys
and 12 years in girls).14
In this study, the expense of the GH therapy used for all
the patients with GHD was qualified and paid by Bureau of
National Health Insurance, Department of Health, Execu-
tive Yuan, Taiwan. All the patients received the fixed dose
0.48 IU/kg/wk (0.16 mg/kg/wk) of recombinant GH, from
either Saizen (Merck Serono, Modugno, Italy), Norditropin
(Novo Nordisk A/S, Bagsvaerd, Denmark), or Genotropin
(Pfizer Inc., Puurs, Belgium). GH was divided equally into
daily doses and administered subcutaneously before sleep.
All the patients received GH therapy for at least 1 year. The
continuous application of GH replacement therapy was
qualified by the Bureau of National Health Insurance
annually, and the criteria were such that the minimum
height velocity after GH therapy was to be >2 cm/y
measured before initiating GH therapy and skeletal
age < 16 years in boys and < 14 years in girls.14
A total of 48 patients underwent a re-evaluation of GH
status using one or two pharmacological stimuli (insulin
stimulation or/and clonidine test) at least 6 months after
discontinuation of GH treatment. If the GH peak level in
any one GH re-evaluation was observed to be more than
10 mg/L, the patient was reallocated to the TGHD group
from his or her initial diagnostic group (IGHD or MPHD).
Statistical analysis
Continuous data were presented as mean  standard
deviation, and categorical data were presented as number
(percentage). The comparative study among the groups was
made by one-way ANOVA following the Bonferroni post hoc
procedure for continuous variables. Fisher’s exact tests
were performed to compare categorical variables between
groups. The association between various baselineparameters and height increment was identified using
Pearson’s product-moment correlation. To identify the
predictive factors for increase in height, the baseline
parameters that had been significant in former univariate
correlation analyses (p < 0.05) were then entered into
a further multiple linear regression analysis. Results of the
regression analysis were presented as unstandardized
regression coefficients (B) with their corresponding 95%
confidence intervals and p values.
A value of p < 0.05 indicated statistical significance.
Analyses were carried out using SPSS for Windows (SPSS
15.0, SPSS Inc., Chicago, IL, USA).Results
Baseline characteristics of patients with GHD
The baseline characteristics of all the patients in the three
groups of GHD are summarized in Table 1. The result of one-
way ANOVA showed that the age at diagnosis of TGHD
was significantly greater than that for IGHD and MPHD
(11.05  1.85 vs 8.25  3.12 and 8.66  4.06 years). Patients
with MPHD had a lower GH peak during the GH provocation
test than did those with IGHD and TGHD (2.75  2.31 vs
7.65  2.45 and 6.63  2.15 mg/L). Patients with MPHD
had a significantly lower SDS for height (3.78  1.44 vs
2.34  0.61) and height-target height (Ht-TH) SDS
(2.96  1.44 vs 1.22  0.89) than those with TGHD.
Patients with MPHD had significantly lower IGF-1 levels
(27.74  25.03 vs 196.80  129.76 ng/mL) and IGF-1 SDS
(2.45  0.84 vs 0.76  1.47) than the TGHD group. The
difference in the gender ratio was found to be significant
(p Z 0.021), the percentage of males being highest for
TGHD (87%) and lowest for MPHD (50%).
Patients in the MPHD group had a comparatively higher
incidence of pituitary hypoplasia (n Z 10, 83%), pituitary
stalk dysgenesis (n Z 6, 50%; three subjects showed
absence of a stalk, two had a thin stalk, and one had an
interrupted stalk), and posterior lobe dysgenesis (n Z 6,
50%; five subjects had an ectopic posterior lobe and one
Table 1 Baseline characteristics of all patients with growth hormone deficiency.
Characteristics Total Patient group (n) p
(n Z 51) TGHD (31) IGHD (8) MPHD (12)
Gender, male (%) 38 (75) 27 (87) 5 (63) 6 (50) 0.021
Age of diagnosis (CA) (y) 51 11.05  1.85 8.25  3.12y 8.66  4.06y 0.007
Peak GH (mg/L) 51 6.63  2.15 7.65  2.45 2.75  2.31yz <0.001
TH SDS 51 1.12  0.74 0.96  0.34 0.82  0.80 0.463
Puberty (%) 6 (12) 3 (10) 2 (25) 1 (8) 0.472
Age at start (y) 51 11.37  1.81 8.51  3.08y 9.81  4.12 0.021
HV (cm/y) 51 4.12  1.18 4.21  1.55 3.54  1.23 0.348
Ht SDS 51 2.34  0.61 2.78  0.82 3.78  1.44y <0.001
Ht-TH SDS 51 1.22  0.89 1.82  0.66 2.96  1.44y <0.001
BMI SDS 51 0.33  0.92 0.17  1.07 0.12  0.88 0.373
BA (y) 51 8.19  1.89 5.47  3.77y 5.60  2.86y 0.002
BA-CA (y) 51 2.96  0.96 2.79  1.77 4.02  2.26 0.087
IGF-1 (ng/mL) 51 196.80  129.76 134.17  151.88 27.74  25.03y <0.001
IGF-1 SDS 51 0.76  1.47 1.34  1.40 2.45  0.84y 0.002
Brain MRI (%) 50 (98) 31 (100) 7 (88) 12 (100) 0.157
Pituitary hypoplasia (%) 17 (34) 6 (19) 1 (14) 10 (83) <0.001
Pituitary stalk dysgenesis (%) 7 (14) 0 (0) 1 (14) 6 (50) <0.001
Posterior lobe dysgenesis (%) 7 (14) 0 (0) 1 (14) 6 (50) <0.001
Other anomalies (%) 9 (18) 5 (16) 1 (14) 3 (25) 0.864
Continuous data were presented as mean  standard deviation, and categorical data were presented as number (percentage). All
comparisons of continuous variables among groups were made by one-way ANOVA following the Bonferroni post hoc procedure.
y p < 0.05 vs TGHD.
z p < 0.05 vs IGHD.
BAZ bone age; BMIZ body mass index; CAZ chronological age at diagnosis; GHZ growth hormone; IGF-1Z insulin-like growth factor;
IGHD Z isolated growth hormone deficiency; Ht Z height; HV Z height velocity; MPHD Z multiple pituitary hormone deficiency;
MRIZmagnetic resonance imaging; SDSZ standard deviation score; TGHDZ transient growth hormone deficiency; THZ target height.
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two groups. The percentage of other anomalies between
the three groups was not significantly different. (Table 1).
Effect of GH therapy
The changes in height velocity and height SDS for each
individual group from the commencement to the third year
of GH treatment is shown in Fig. 2. In each group, the initial
response to GH therapy was a vigorous rise in the growth
rate, followed by a gradual decline and then stabilization.
In all groups, the mean height SDS improved with therapy,
the increment ranging from 0.67 to 1.98 SDS.
Longitudinal data on the characteristics and parameters
of response during the first 2 years of GH therapy are shown
in Table 2. The variables, including age, height velocity,
height SDS, Ht-TH SDS, body mass index (BMI) SDS, BA, BA-
CA, IGF-1, and IGF-1 SDS, were recorded annually during GH
treatment. The MPHD group had a significantly higher
height velocity in the first year than the TGHD group
(9.99  2.75 vs 7.61  1.46 cm/y). After 1 year of GH
treatment, there was no significant difference in BMI SDS,
BA-CA, IGF-1 level, and IGF-1 SDS among the three groups.
The MPHD group had a significantly lower value for Ht SDS
(2.86  1.28 vs 2.05  0.72 SDS) and Ht-TH SDS
(2.04  1.26 vs 0.94  0.94 SDS) than the TGHD group. In
addition, the TGHD group had a greater BA than the IGHD
and MPHD groups (9.97  2.31, 6.50  4.10, and 7.12  3.40
years, respectively).A total of 26, 6, and 12 subjects received 2-year GH
therapy in the TGHD, IGHD, and MPHD groups, respectively.
There was no significant difference in height velocity,
height SDS, Ht-TH SDS, BMI SDS, IGF-1 level, and IGF-1 SDS
among three groups after the second year of GH treatment.
The MPHD group had a significant BA delay (BA-CA
3.22  2.43 vs 1.13  1.40 years) compared to the TGHD
group in the second year. In addition, the TGHD group had
a greater BA than the IGHD and MPHD groups (11.83  2.53,
7.46  4.64, and 8.31  3.67 years, respectively).Adverse effects during GH treatment
Two patients complained of pain in their extremities,
cramps, or soreness during GH treatment. Two patients
had complaints of headache. One patient had mild scoli-
osis. One patient developed a smooth muscle tumor of
uncertain malignant potential on the right thigh after 1
year of GH treatment, and GH was stopped for 1 year. The
patient restarted GH treatment 1 year after operation,
and the GH treatment was continued for 3 years. So far,
this patient has had no recurrence of his smooth muscle
tumor.Correlation and regression analysis
Correlations between height increment and various baseline






































Figure 2 Change in (A) height velocity and (B) standard
deviation score (SDS) of each individual group from the start
to the fifth year of growth hormone treatment. Line plots
indicate the mean scores for height velocity and SDS.
IGHDZ isolated growth hormone deficiency; MPHDZ multiple
pituitary hormone deficiency; TGHD Z transient growth
hormone deficiency.
Growth hormone therapy in growth hormone deficiency 359treatment with GH are shown in Table 3. Change in height
SDS in the first year had a significant negative correlation
with the following variables: peak GH (r Z 0.52,
p< 0.001), pretreatment height SDS (rZ0.49, p< 0.001),
and Ht-TH SDS (rZ 0.49, p < 0.001) (Fig. 3). The authors
extended the duration of GH treatment and found that
change in height SDS in the first 2 years was significantly
negatively correlated with peak GH (rZ 0.51, p < 0.001),
IGF-1 SDS (r Z 0.35, p Z 0.022), height SDS (r Z 0.60,
p < 0.001), BA-CA (r Z 0.46, p Z 0.001), and Ht-TH SDS
(rZ 0.50, p Z 0.001) (Fig. 3).
Table 4 shows the predictive factors for height incre-
ments after 1 and 2 years of GH treatment in patients with
GHD. The variables that had been significant in the corre-
lation analysis (including pretreatment GH peak, height
SDS, and Ht-TH SDS) were treated as independent variables
and entered into a multiple linear regression analysis.
Results showed that the pretreatment GH peak value was
found to be significantly associated with height increments
after 1 year of GH treatment (B Z 0.07, p Z 0.014).
Variables significant in the correlation analysis (including
pretreatment GH peak, IGF-1 SDS, height SDS, BA-CA, and
Ht-TH SDS) were treated as independent variables to
predict height increments after 2 years of GH treatment.
Pretreatment height SDS was the only independently
predictive factor (B Z 0.34, pp Z 0.048).Discussion
The study reveals that the patients with MPHD represented
the most severe form of GHD and had lower peak GH,
pretreatment height SDS, Ht-TH SDS, IGF-1, and IGF-1 SDS,
as well as greater BA retardation, than the other two groups.
There was no significant difference observed between TGHD
and IGHD in terms of peak GH, height velocity, height SDS,
Ht-TH SDS, BA-CA, IGF-1, and IGF-1 SDS.
The diagnosis of GHD during childhood and adolescence
is still controversial,1 and no gold standard has so far
existed for the diagnosis of GHD.15 This is related to the
coherence between severe GHD and normality, marked
variability in GH assays, arbitrary “cut-offs” used to define
GHD from GH stimulation tests, and the lack of reproduc-
ibility of GH stimulation tests.15 Other tests for the integ-
rity of the GH axis, such as for IGF-1 and IGF binding
protein-3, have been therefore considered as a diagnostic
component for GHD.1,6 The patients with MPHD also had
a higher possibility of permanent GHD. Tauber et al3
reported that most (62%) GHD patients have a normal GH
test at the end of GH therapy. Similarly, 31 (65%) of 48
patients undergoing re-evaluation of GH secretion after
treatment were reassigned to TGHD in our study; a total of
29 (78.4%) of the 37 patients with IGHD had a normal GH
response during GH re-evaluation. Only two (18.2%) of the
11 patients with MPHD had normal GH and other hormonal
responses when re-evaluated.
On MRI, MPHD patients had a significantly higher
frequency of pituitary hypoplasia, pituitary stalk dysgenesis,
and ectopic posterior lobe than the other two groups in our
study. According to the consensus guidelines of the Growth
Hormone Research Society, MRI of the brain with an emphasis
on the hypothalamic-pituitary region should be carried out in
children finally diagnosed as having GHD.1 MRI of the hypo-
thalamus and pituitary gland can help to clinically evaluate
the severity of GHD and the response to GH treatment.6,16
GH therapy was more effective in terms of linear growth
in the MPHD group than the IGHD and TGHD groups. The
initial response to GH therapy was a vigorous rise in the
growth rate, followed by a gradual decline and then
stabilization.17 Estimating peak GH before treatment was
an important predictive factor for the effect of GH in our
patients with GHD. Peak GH has a significantly negative
correlation to height increment after 1 and 2 years of GH
therapy. GH provocation tests are still very important,
although there are a large number of TGHD and false-
positive results.17
IGF-1 level before treatment was not a significant
predictive factor for the effect of the first 2 years of GH
therapy in this study. However, IGF-1 SDS before treatment
had a significant negative correlation with height increment
only after 2 years of GH therapy. Therefore, IGF-1 SDS,
rather than IGF-1, could be considered as a diagnostic
component for GHD.1,6
Several attempts have been made to define and predict
the growth response. In 1981, Frasier et al18 reported
a doseeresponse curve for human GH based on patients’
body weight. Dose-responsiveness has also been considered
in more recent studies using higher GH dosages and
measures of pubertal status.19e21 No uniform response of
Table 2 Longitudinal data on the characteristics and parameters of response during the first two years of growth hormone
therapy.
Year/characteristics Total Patient group p (ANOVA)
TGHD (31) IGHD (8) MPHD (12)
First year
Number of subjects 51 31 8 12
Age (y) 51 12.36  1.79 9.46  3.06y 10.79  4.14 0.020
HV (cm/y) 51 7.61  1.46x 8.14  1.92 9.99  2.75 0.002
Ht SDS 51 2.05  0.72 2.23  0.76 2.86  1.28y 0.035
Ht-TH SDS 51 0.94  0.94 1.27  0.73 2.04  1.26y 0.008
BMI SDS 51 0.30  0.84 0.001  1.07 0.28  0.90 0.689
BA (y) 50 9.97  2.31 6.50  4.10y 7.12  3.40y 0.002
BA-CA (y) 50 2.23  1.21 2.72  1.98 3.48  2.14 0.084
IGF-1 34 352.60  172.84 194.08  128.45 231.94  145.85 0.093
IGF-1 SDS 34 0.21  2.16 0.73  1.36 0.61  1.75 0.829
Second year
Number of subjects 44 26 6 12
Age (y) 44 13.29  1.78 9.76  3.25y 11.79  4.13 0.020
HV (cm/y) 44 7.85  1.95 5.97  1.22 7.25  1.81 0.084
Ht SDS 44 1.71  0.69 2.06  0.89 2.33  1.22 0.139
Ht-TH SDS 44 0.58  1.03 1.09  0.71 1.51  1.29 0.050
BMI SDS 44 0.38  0.92 0.11  0.83 0.19  0.91 0.737
BA (y) 44 11.83  2.53 7.46  4.64y 8.31  3.67y 0.001
BA-CA (y) 44 1.13  1.40 1.90  1.69 3.22  2.43y 0.006
IGF-1 (ng/mL) 22 392.00  202.28 139.33  31.66 175.98  131.04 0.029
IGF-1 SDS 22 0.55  1.43 0.89  0.68 1.26  1.01 0.572
Data were presented as mean  standard deviation. All comparisons among groups were made by one-way ANOVA following the Bon-
ferroni post hoc procedure.
y p < 0.05 vs TGHD.
x p < 0.05 vs MPHD.
BA Z bone age; BMI Z body mass index; CA Z chronological age at diagnosis; IGF-1 Z insulin-like growth factor; IGHD Z isolated
growth hormone deficiency; Ht Z height; HV Z height velocity; MPHD Z multiple pituitary hormone deficiency; SDS Z standard
deviation score; TGHD Z transient growth hormone deficiency; TH Z target height.
Table 3 Correlations between height increment and
various baseline parameters in all patients with growth
hormone deficiency after 1 and 2 years of treatment with
growth hormone.
DHt SD score 0e1 y DHt SD score 0e2 y
n r p n r p
Pretreatment variables
Peak GH 51 0.52 <0.001 44 0.51 <0.001
IGF-1 50 0.23 0.110 43 0.29 0.059
IGF-1 SDS 50 0.16 0.258 43 0.35 0.022
Height SDS 51 0.49 <0.001 44 0.60 <0.001
BA-CA (y) 51 0.25 0.081 44 0.46 0.001
Age at start (y) 51 0.17 0.220 44 0.06 0.692
Ht-TH SDS 51 0.49 <0.001 44 0.50 0.001





34 0.21 0.230 29 0.04 0.851
BAZboneage;CAZchronological ageatdiagnosis;GHZgrowth
hormone; IGF-1 Z insulin-like growth factor; Ht Z height;
SDSZ standard deviation score; THZ target height.
360 Y.-H. Huang et al.all children to a given dose of GH has been seen. In 2010,
Cohen et al22 developed a new GH dosing algorithm based
on patients’ IGF-1 responses.
In addition to doseeresponse models and reports,
various models of prediction have been established. In
1993, Blethen et al23 reported that chronological age, log of
maximum GH response, weight (adjusted for height), log of
GH dose, and mid-parietal height could predict the
response to the first year of GH treatment. In 1997, Kris-
tro¨m et al24 reported that IGF-1 SDS, log of maximum GH
response, initial age, weight SDS at 1 year of age, and short-
term change in IGF-1 SDS could explain 58% of the variation
in GH response.
Ranke et al25 in 1999 analyzed the Kabi Pharmacia
International Growth Study data and reported that the
variables for the first-year growth response were the
natural log of the maximum GH response, chronological
age, Ht-TH SDS, body weight SDS, GH dose, and birthweight
SDS. Four predictors for the second-, third-, and fourth-
year growth responses were height velocity during the
previous year (positively correlated), body weight SDS
(positively correlated), chronological age (negatively
correlated), and natural log of weekly GH dose (positively
correlated). Chen et al14 in 2001 analyzed 23 Taiwanese
patients undergoing GH treatment and reported that their
Figure 3 Individual values for parameters (peak growth hormone, height SDS, Ht-TH SDS) at the start of growth hormone
treatment plotted against individual 1-year and 2-year growth responses, expressed as height SDS. Ht-TH Z height-target height;
SDS Z standard deviation score.
Growth hormone therapy in growth hormone deficiency 361final height was correlated to the initial height SDS, TH SDS,
predicted height by the BA at the beginning of treatment,
and height SDS at the onset of puberty.
In the current study, the dosage of GH given to our
patients with GHD was low and fixed at 0.48 IU/kg/wk
(0.16 mg/kg/d) according to the policy of the Bureau of
National Health Insurance in Taiwan. In spite of a low dose
of GH therapy, we observed that change in height SDS in thefirst year had a significant negative correlation with the
following variables: peak GH, pretreatment height SDS, and
Ht-TH SDS. The change in height SDS in the first 2 years had
a significant negative correlation with peak GH, IGF-1 SDS,
height SDS, BA-CA, and Ht-TH SDS. The significant correla-
tion with change in height SDS in the first 3 years was
similar to changes in the first 2 years. After using multiple
linear regressions, pretreatment GH peak value was shown
Table 4 Predicting factors, using multiple linear regression analysis, for height increments after 1 and 2 years of growth
hormone therapy in all patients with GHD, respectively.
DHt SD score 0e1 y (n Z 51) DHt SD score 0e2 y (n Z 43)
B 95% CI p B 95% CI p
Pretreatment variables
Peak GH 0.07 0.12 to 0.01 0.014 0.07 0.15 to 0.02 0.109
IGF1
IGF1 SDS 0.04 0.13 to 0.21 0.599
Height SDS 0.11 0.31 to 0.10 0.308 0.34 0.682 to 0.003 0.048
BA-CA (y) 0.10 0.25 to 0.05 0.180
Age at start (y)
Ht-TH SDS 0.06 0.24 to 0.12 0.503 0.04 0.26 to 0.34 0.777
TH SDS
Short-term variables
DIGF-1 SDS 0e1 y
BZ unstandardized regression coefficient; BAZ bone age; CAZ chronological age at diagnosis; CIZ confidence interval; GHZ growth
hormone; IGF-1 Z insulin-like growth factor; Ht Z height; SDS Z standard deviation score; TH Z target height.
362 Y.-H. Huang et al.to be the predicting factor for height increments after 1
year of GH treatment. The predicting factor for height
increments after 2 years of GH treatment was height SDS.
The mainstay of MPHD is replacement with the appro-
priate hormones. Thyroxine should be given if serum free or
total thyroxine level is low. Growth should be meticulously
monitored, and if height velocity is poor and GHD is
confirmed by stimulation tests, GH treatment should be
given until linear growth ceases. Sex steroids such as
estrogen or testosterone should be commenced at puberty
if gonadotropin deficiency is confirmed.26
Our study had many limitations, such as inadequate
sample size and three (6%) of the 51 patients the patients
not receiving GH re-evaluation after completion of GH
treatment. However, these three patients belong to MPHD
group, and only two (18%) of the 11 patients with MPHD
were reassigned to the TGHD group after re-testing of GH.
In conclusion, the administration of GH to children with
GHD results in a pronounced acceleration of linear growth,
mostly during the first year of treatment, particularly in
MPHD group. The diagnosis of GHD requires comprehensive
auxological, biochemical (GH provocation test, IGF-1, and
IGF-binding protein-3), and brain MRI assessment. We
suggestively conclude that the patients with GHD, espe-
cially IGHD, must undergo re-evaluation of GH secretion
after completion of GH therapy.Supplementary material
Supplementary material associated with this article can be
found, in the online version, at doi:10.1016/j.jfma.2011.
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